Table 2 Comparison of asthma patients vs. asthma patients using the mobile app
Parameters | Evaluation time | Asthma patients (N = 54) | Asthma patients using mobile app (N = 39) | p-valuec |
|---|---|---|---|---|
ACT scorea | T 1 | 19.00 (19.00–20.00) | 21.00 (20.00–22.00) | < 0.001 |
T2 | 20.00 (20.00–22.00) | 23.00 (23.00–24.00) | < 0.001 | |
T3 | 21.00 (20.00–22.00) | 23.00 (23.00–24.00) | < 0.001 | |
T4 | 21.00 (20.00–22.00) | 23.00 (23.00–24.00) | < 0.001 | |
Reliever inhaler usedb | T 1 | 40 (74.07%) | 9 (23.08%) | < 0.001 |
T2 | 21 (38.88%) | 4 (10.26%) | 0.002 | |
T3 | 14 (25.92) | 1 (2.56%) | 0.003 | |
T4 | 17 (31.48%) | 4 (10.26%) | 0.016 | |
Exacerbationsb | T 1 | 25 (46.30%) | 4 (10.30%) | < 0.001 |
T2 | 8 (14.8%) | 5 (12.8%) | 0.784 | |
T3 | 9 (16.70%) | 1 (2.60%) | 0.041 | |
T4 | 13 (24.10%) | 4 (10.30%) | 0.089 | |
Exacerbation with hospitalizationb | T 1 | 0 (0%) | 0 (0%) | NA |
T2 | 1 (12.5%) | 0 (0%) | 0.615 | |
T3 | 1 (11.12%) | 0 (0%) | 0.900 | |
T4 | 5 (38.46%) | 0 (0%) | 0.261 | |
Exacerbations without hospitalizationsb | T 1 | 25 (100%) | 4 (100%) | NA |
T2 | 7 (87.5%%) | 5 (100%) | 0.615 | |
T3 | 8 (88.89%) | 1 (100%) | 0.900 | |
T4 | 8 (61.54%) | 4 (100%) | 0.261 |